First, the Environmental Protection Agency (EPA) under the Trump administration refused to ban the import, sale and use of the known carcinogen asbestos like more than 65 other countries around the world, and opted instead to allow new uses of dangerous mineral on a case-by-case basis. Now the EPA announced that it would not ban the widely used chemical chlorpyrifos, used in some weed killers, despite the agency’s own experts warning that it can cause serious health problems in children.
Chlorpyrifos is the active ingredient in the commercial brand Lorsban, and is widely sprayed on fruit, nuts, cereal and vegetables. In 2015, the Obama administration said it would ban chlorpyrifos after EPA provided studies that found that the chemical could damage brain development in children. The decision was reversed in 2017 by then-EPA administrator Scott Pruitt, which resulted in a slew of lawsuits. In April, a federal appeals court gave the EPA until July to decide whether it would ban chlorpyrifos.
Both the chemical industry and farmers have lobbied to keep the herbicide on the market, and apparently have won. The EPA in a statement said it would continue to monitor chlorpyrifos through 2022.
Also in April, the EPA reaffirmed its position on glyphosate, the active ingredient in the widely used weed killer Roundup, saying that “there are no risks to public health when glyphosate is used in accordance with its current label.” The agency’s announcement goes against the World Health Organization’s International Agency for Research on Cancer’s decision in 2015 to classify glyphosate as a probable carcinogen.
Bayer, which acquired Roundup maker Monsanto last year, faces more than 12,000 lawsuits from people who say exposure to glyphosate caused them to develop non-Hodgkin lymphoma. Bayer has faced three trials and lost all three, one of which resulted in a $2 billion verdict.
Our firm is currently representing hundreds of clients who have been exposed to Roundup and developed Non-Hodgkin’s Lymphoma. Our Roundup litigation team would welcome the opportunity to speak with you regarding these cases. Contact John Tomlinson, Andrew Banks or Grant Cofer for more information.